Gabapentin is a gamma-aminobutyric acid derivative, and was approved for the treatment of neuropathic pain by the U.S. Food and Drug Administration in 2002. However, little evidence is available on the effects and me-chanisms of action of gabapentin during the migraine attack period. A recent study by Yanbo Zhang and colleague from Xuanwu Hospital, Capital Medical University in China showed that excitatory amino acids and protein kinase C are involved in the formation and maintenance of central sensitization during migraine. Gabapentin can decrease neuronal excitability in spinal trigeminal nuclei and inhibit the formation of central sensitization during migraine by reducing excitatory amino acid content in the cerebrospinal fluid and by inhibiting protein kinase C activation. These findings were published in the Neural Regeneration Research (Vol. 8, No. 32, 2013).
Article: " Gabapentin inhibits central sensitization during migraine," by Yanbo Zhang1, 2, Guo Shao3, Wei Zhang4, Sijie Li1, Jingzhong Niu2, Dongmei Hu2, Mingfeng Yang2, Xunming Ji1 (1 Institute of Hypoxia Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; 2 Department of Neurology, Affiliated Hospital of Taishan Medical University, Tai'an 271000, Shandong Province, China; 3 Biomedical Research Center, Baotou Medical College, Baotou 014060, Inner Mongolia Autonomous Region, China; 4 Department of Gastroenterology, Second Affiliated Hospital of Baotou Medical College, Baotou 014010, Inner Mongolia Autonomous Region, China)
Zhang YB, Shao G, Zhang W, Li SJ, Niu JZ, Hu DM, Yang MF, Ji XM. Gabapentin inhibits central sensitization during migraine. Neural Regen Res. 2013;8(32):3003-3012.
Contact: Meng Zhao
Neural Regeneration Research
Full text: http://www.sjzsyj.org/CN/article/downloadArticleFile.do?attachType=PDF&id=773
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.